Open Peer Review on Qeios

MAG-Tn3/AS15 Vaccine

National Cancer Institute

Source

National Cancer Institute. MAG-Tn3/AS15 Vaccine. NCI Thesaurus. Code C120555.

A vaccine containing synthetic multiple antigenic glycopeptide (MAG) composed of tri T n glycotope (MAG-T n3), which is comprised of a dendrimeric, nonimmunogenic lysine core linked to a tetravalent peptidic CD4+ T-cell epitope backbone and each attached to three T n antigens (tri-T n cluster), combined with the immunoadjuvant AS15, with potential antineoplastic activity. Upon administration of the MAG-T n3/AS15 vaccine, MAG-T n3 induces the production of tumor-specific anti-T n glycosidic antibodies, which results in antibody-dependent cell cytotoxicity (ADCC) against T n-expressing tumor cells. T he T n carbohydrate antigen, a tumor-associated antigen (T AA), is overexpressed in a number of tumor cell types. The tri-T n clusters mimic carbohydrate structures found on tumor cells. T he T -cell epitope stimulates effective T -cell responses. AS15, a potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid (MPL), and QS-21, increases the immune response against the T n antigens.